Laure Bouchez

Title: Laure Bouchez: Innovator in Bispecific Antibodies

Introduction

Laure Bouchez is a prominent inventor based in La Chaux-de-Fonds, Switzerland. She has made significant contributions to the field of immunology, particularly through her innovative work on bispecific antibodies. Her research focuses on developing novel therapeutic solutions for autoimmune and proliferative diseases, including various forms of cancer.

Latest Patents

Laure Bouchez holds a patent for her invention titled "CD47-CD38 bispecific antibodies." This patent describes a novel class of bispecific heterodimeric immunoglobulins that target both the human CD47 antigen and the human CD38 antigen. The invention includes antibodies that comprise an anti-CD38 heavy chain variable region and a light chain variable region, as well as an anti-CD47 heavy chain variable region and a light chain variable region. The application of these bispecific antibodies is particularly relevant for treating hematologic malignancies and solid tumors.

Career Highlights

Laure Bouchez is associated with Igi Therapeutics SA, where she continues to advance her research in immunotherapy. Her work has the potential to revolutionize treatment options for patients suffering from various cancers and autoimmune disorders. With her innovative approach, she is paving the way for new therapeutic strategies in the medical field.

Collaborations

Laure collaborates with talented professionals in her field, including Blandine Pouleau and Marie-Agnes Doucey. These collaborations enhance her research efforts and contribute to the development of groundbreaking therapies.

Conclusion

Laure Bouchez is a trailblazer in the field of bispecific antibodies, with a focus on addressing critical health challenges. Her innovative work at Igi Therapeutics SA and her patent on CD47-CD38 bispecific antibodies highlight her commitment to advancing medical science. Through her contributions, she is making a significant impact on the treatment of cancer and autoimmune diseases.